Study study type PathologyT1T0Patientssample sizesROB Results

es-BC - TNBC - NA - all population breast cancer - triple negative es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA) es-BC - TNBC - NA - all population

versus placebo
olaparib
OlympiA (BIG 6-13, NSABP B-55) unpublished
  NCT02032823
RCTes-BC - TNBC - NA - all populationolaparibplacebopatients with human epidermal growth factor receptor 2 (HER2)–negative early breast cancer with BRCA1 or BRCA2 germline pathogenic or likely pathogenic variants and high-risk clinicopathological factors921 / 915NA
conclusif
  • demonstrated 32 % decrease in deaths (OS) (PE)
  • demonstrated 42 % decrease in iDFS (PE)